COMP <GO>
TMDX vs INMD // FREE CASH FLOW YIELD
TransMedics Group Inc. (NASDAQ) VS. InMode Ltd. (NASDAQ) • 15-METRIC TALLY: TMDX 4
— INMD 6
▲ FREE CASH FLOW YIELD LEADER: INMD
LAST: $65.99 (-1.68%) • MKT CAP: $2.33B
fcf-yield
5.74%
LAST: $13.22 (-2.15%) • MKT CAP: $776.6M
fcf-yield
10.85%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TMDX VS. INMD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TMDX | INMD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.90% | 78.50% | -18.60 | INMD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.10% | 17.70% | +0.40 | TMDX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 14.6x | 5.5x | +9.10 | INMD | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 5.74% | 10.85% | -5.11 | INMD | /fcf-yield <GO> |
| Operating Margin | 17.90% | 23.00% | -5.10 | INMD | /operating-margins <GO> |
| Net Profit Margin | 31.40% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 37.10% | -6.20% | +43.30 | TMDX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.50 | 9.20 | -5.70 | INMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 4/9 | +4.00 | TMDX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 32.5 | 36.3 | -3.80 | INMD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.2x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.33B | $776.6M | $1.55B | TMDX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TMDX REV | INMD REV | TMDX GROSS % | INMD GROSS % | TMDX FCF | INMD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $605.5M | $370.5M | 59.9% | 78.5% | $133.6M | $84.3M |
| FY 2024 | $441.5M | $394.8M | 59.4% | 80.3% | -$80.9M | $132.0M |
| FY 2023 | $241.6M | $492.0M | — | — | -$13.0M | $176.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TMDX // BETA —
INMD // BETA —